Pharmaceutical Intermediates Velpatasvir API Velpatasvir Powder Velpatasvir

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung Velpatasvir
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Product Name: Velpatasvir
• Name: Velpatasvir Powder
• Appearance: White Powder
• Color: White Color
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 1377049-84-7
• Mf: C49h54n8o8
• MW: 883
• Density: 1.314
• Refractive Index: 1.643
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 1000kg/Month

Product Description

Pharmaceutical Intermediates Velpatasvir API Velpatasvir Powder Velpatasvir

Product Description

Product Details

Product name	Velpatasvir
Appearance	White powder
CAS NO.	1377049-84-7
MF	C49H54N8O8
MW	883

Velpatasvir (1377049-84-7) is an extremely potent pan-genotypic hepatitis C virus (HCV) NS5A inhibitor.1 It is a component of Epclusa and Vosevi, two clinically useful medications with 98% and 97%, respectively, cure rates for HCV. It displayed EC50's for GTs 1-4, 6a ranging from 6-16 pM, GT5a at 75 pM, and GT6e at 130 pM. Velpatasvir also displayed an excellent barrier to viral resistance. It has been shown in silico, that velpatasvir binds to the SARS-Co V-2 spike protein and may be a potential therapeutic.

Application&Function

Verapatavir is an NS5A inhibitor in patients with hepatitis C virus (HCV) infection.
Velpatasvir is a universal NS5A inhibitor.
It can be used to treat adult patients infected with hepatitis C virus type 1~6, and can be used only for patients without cirrhosis or compensatory cirrhosis, or can be used with ribavirin to treat patients with decompensated cirrhosis. Verapatavir is the second generation NS5A inhibitor, which has good antiviral activity in vitro against all genotypes of HCV and common NS5A mutations and drug resistance mutations.

Specification